Questioning Ethics of Costly Drugs for Metastatic Cancer

November 17, 2016

(Medscape) – Many commentators have raised concern about very expensive cancer drugs that offer only a short survival benefit, but a new voice questions the ethics of such treatment. “Spending a six figure sum to prolong a life by a few weeks or months is already unaffordable,” but it is also “inappropriate” for the many cancer patients who “will almost inevitably die from solid tumor metastases,” says Peter Wise, a former consultant physician at Charing Cross Hospital and Imperial College School of Medicine, London, England.